BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 12:00 p.m. ET / 9:00 a.m. PT.

Ted W. Love, president and chief executive officer of GBT, called the approval of Oxbryta a major milestone for the company and for patients with sickle cell disease.

If you run a team, you know the power of motivation. Yes, you likely hired people who are very self-motivated and want to succeed for their own satisfaction, but don’t discount what a little appreciation can do to boost someone up.

Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors. The early thinking on biotech is yes.

Imagine if an ultrasound could be used as a quantitative tool to measure fat in the liver and detect non-alcoholic fatty liver disease. What seems imaginative is close to becoming reality at Endra Life Sciences.

The so-called “heart-in-a-jar” will be created from human stem cells and designed to reproduce key phenotypic characteristics of heart failure.

Could fungi become sources for new drugs to treat a myriad of diseases and disorders? Researchers at the Hubrecht Institute in the Netherlands aim to find out.

Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.

The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.